AER 1571272 is a spontaneous case, received on 30/Apr/2015 from a other healthcare professional via a Marketed
Health Products Directorate (MHPD), health authority, Canada (reference number:E2B00185257 ) and concerns a 
50 year old female patient who had drug ineffective and developed adrenal insufficiency, arthralgia, balance 
disorder, cognitive disorder, coordination abnormal, cough, demyelination, depressed mood, depression, dizziness, 
dry mouth, dysphagia, electric shock, fatigue, hyperhidrosis, hypotension, infusion related reaction, intervertebral 
discitis, multiple sclerosis, nausea, neuropathy peripheral, pain, post-traumatic stress disorder, progressive 
multifocal leukoencephalopathy, rheumatoid arthritis, syncope, temperature intolerance, throat irritation, ulcer and 
urticaria whilst being treated with rituximab (Rituxan), aspirin, diphenhydramine hydrochloride, etanercept (Enbrel), 
esomeprazole magnesium trihydrate/naproxen, cetirizine hydrochloride (Reactine).
The patient's concomitant medications included paracetamol, atenolol, cetirizine hydrochloride, diphenhydramine 
hydrochloride, duloxetine hydrochloride, methylprednisolone, methylprednisolone, lansoprazole, vitamin E, 
zopiclone. No medical history, concurrent conditions or past drugs were reported.
On an unknown date, the patient started therapy with intravenous rituximab solution 1000 mg (frequency not 
reported), aspirin (dose, frequency and route not reported), diphenhydramine hydrochloride (dose, frequency and 
route not reported), subcutaneous etanercept solution (dose, frequency not reported) ,esomeprazole magnesium 
trihydrate/naproxen (dose, frequency and route not reported), cetirizine hydrochloride (dose, frequency and route 
not reported) for unknown indication. On an unspecified date, she had drug ineffective and developed adrenal 
insufficiency, arthralgia, balance disorder, cognitive disorder, coordination abnormal, cough, demyelination, 
depressed mood, depression, dizziness, dry mouth, dysphagia, electric shock, fatigue, hyperhidrosis, hypotension, 
infusion related reaction, intervertebral discitis, multiple sclerosis, nausea, neuropathy peripheral, pain, post-
traumatic stress disorder, progressive multifocal leukoencephalopathy, rheumatoid arthritis, syncope, temperature 
intolerance, throat irritation, ulcer and urticaria.
At the time of report, the events adrenal insufficiency, arthralgia, balance disorder, cognitive disorder, coordination 
abnormal, cough, demyelination, depressed mood, depression, dizziness, dry mouth, dysphagia, electric shock, 
fatigue, hyperhidrosis, hypotension, infusion related reaction, intervertebral discitis, multiple sclerosis, nausea, 
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 405 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
neuropathy peripheral, pain, post-traumatic stress disorder, progressive multifocal leukoencephalopathy, 
rheumatoid arthritis, syncope, temperature intolerance, throat irritation, ulcer and urticaria were persisting. It was 
unknown if rituximab, aspirin, diphenhydramine hydrochloride, etanercept, esomeprazole magnesium 
trihydrate/naproxen and cetirizine hydrochloride were ongoing or not.
The other healthcare professional did not report a causality between adrenal insufficiency, arthralgia, balance 
disorder, cognitive disorder, coordination abnormal, cough, demyelination, depressed mood, depression, dizziness, 
dry mouth, dysphagia, electric shock, fatigue, hyperhidrosis, hypotension, infusion related reaction, intervertebral 
discitis, multiple sclerosis, nausea, neuropathy peripheral, pain, post-traumatic stress disorder, progressive 
multifocal leukoencephalopathy, rheumatoid arthritis, syncope, temperature intolerance, throat irritation, ulcer, drug 
ineffective, urticaria and rituximab, aspirin, diphenhydramine hydrochloride, etanercept, esomeprazole magnesium 
trihydrate/naproxen, cetirizine hydrochloride.
The other healthcare professional assessed the events drug ineffective, adrenal insufficiency, arthralgia, balance 
disorder, cognitive disorder, coordination abnormal, cough, demyelination, depressed mood, depression, dizziness, 
dry mouth, dysphagia, electric shock, fatigue, hyperhidrosis, hypotension, infusion related reaction, intervertebral 
discitis, multiple sclerosis, nausea, neuropathy peripheral, pain, post-traumatic stress disorder, progressive 
multifocal leukoencephalopathy, rheumatoid arthritis, syncope, temperature intolerance, throat irritation, ulcer and 
urticaria as medically significant.
No further information was provided.
Additional information was received on 07/Dec/2015. Following information has been added to the case: details of 
concomitant medication updated as cymbalta (previously reported as duloxetine hydrochloride).